Humira (adalimumab) is the best‑selling drug in history — it's a subcutaneous injection every 2 weeks. Remicade (infliximab) is intravenous, given every 4‑8 weeks in a clinic. Enbrel (etanercept) is a fusion protein, injected weekly. The US tumor necrosis factor alpha inhibitors market research shows that monoclonal antibodies (Humira, Remicade) hold the largest share, but fusion proteins (Enbrel) are the fastest‑growing. Why? Because fusion proteins have a slightly different mechanism — they don't bind to all TNF forms, which may reduce some side effects.
What's the difference in efficacy? All three work well for rheumatoid arthritis and psoriasis. But for Crohn's disease, Remicade and Humira have more data than Enbrel. The US TNF-alpha inhibitors market trends highlight that the fastest‑growing route of administration is subcutaneous, because patients prefer self‑injection at home.
But choice also depends on insurance coverage. Biosimilars have made Humira more affordable, but some plans still prefer Enbrel.
The bottom line: there's no best TNF inhibitor — the right one depends on your disease, lifestyle, and insurance. Work with your doctor to choose.
